ACRS
Price
$1.56
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
159.17M
37 days until earnings call
PDSB
Price
$1.41
Change
-$0.04 (-2.76%)
Updated
Jun 27 closing price
Capitalization
64.45M
44 days until earnings call
Interact to see
Advertisement

ACRS vs PDSB

Header iconACRS vs PDSB Comparison
Open Charts ACRS vs PDSBBanner chart's image
Aclaris Therapeutics
Price$1.56
Change-$0.00 (-0.00%)
Volume$7.53K
Capitalization159.17M
PDS Biotechnology
Price$1.41
Change-$0.04 (-2.76%)
Volume$313.9K
Capitalization64.45M
ACRS vs PDSB Comparison Chart in %
Loading...
ACRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACRS vs. PDSB commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACRS is a Buy and PDSB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (ACRS: $1.56 vs. PDSB: $1.41)
Brand notoriety: ACRS and PDSB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACRS: 1% vs. PDSB: 54%
Market capitalization -- ACRS: $159.17M vs. PDSB: $64.45M
ACRS [@Biotechnology] is valued at $159.17M. PDSB’s [@Biotechnology] market capitalization is $64.45M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACRS’s FA Score shows that 1 FA rating(s) are green whilePDSB’s FA Score has 0 green FA rating(s).

  • ACRS’s FA Score: 1 green, 4 red.
  • PDSB’s FA Score: 0 green, 5 red.
According to our system of comparison, both ACRS and PDSB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACRS’s TA Score shows that 6 TA indicator(s) are bullish while PDSB’s TA Score has 3 bullish TA indicator(s).

  • ACRS’s TA Score: 6 bullish, 4 bearish.
  • PDSB’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ACRS is a better buy in the short-term than PDSB.

Price Growth

ACRS (@Biotechnology) experienced а +7.59% price change this week, while PDSB (@Biotechnology) price change was -12.96% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

ACRS is expected to report earnings on Aug 06, 2025.

PDSB is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACRS($159M) has a higher market cap than PDSB($64.5M). PDSB YTD gains are higher at: -13.497 vs. ACRS (-37.097). PDSB has higher annual earnings (EBITDA): -33.08M vs. ACRS (-53.49M). ACRS has more cash in the bank: 105M vs. PDSB (40M). ACRS has higher revenues than PDSB: ACRS (17.8M) vs PDSB (0).
ACRSPDSBACRS / PDSB
Capitalization159M64.5M247%
EBITDA-53.49M-33.08M162%
Gain YTD-37.097-13.497275%
P/E RatioN/AN/A-
Revenue17.8M0-
Total Cash105M40M263%
Total DebtN/A19M-
FUNDAMENTALS RATINGS
ACRS vs PDSB: Fundamental Ratings
ACRS
PDSB
OUTLOOK RATING
1..100
7850
VALUATION
overvalued / fair valued / undervalued
1..100
22
Undervalued
36
Fair valued
PROFIT vs RISK RATING
1..100
9897
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
5562
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
10n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACRS's Valuation (22) in the Pharmaceuticals Other industry is in the same range as PDSB (36) in the Pharmaceuticals Major industry. This means that ACRS’s stock grew similarly to PDSB’s over the last 12 months.

PDSB's Profit vs Risk Rating (97) in the Pharmaceuticals Major industry is in the same range as ACRS (98) in the Pharmaceuticals Other industry. This means that PDSB’s stock grew similarly to ACRS’s over the last 12 months.

PDSB's SMR Rating (98) in the Pharmaceuticals Major industry is in the same range as ACRS (98) in the Pharmaceuticals Other industry. This means that PDSB’s stock grew similarly to ACRS’s over the last 12 months.

ACRS's Price Growth Rating (55) in the Pharmaceuticals Other industry is in the same range as PDSB (62) in the Pharmaceuticals Major industry. This means that ACRS’s stock grew similarly to PDSB’s over the last 12 months.

ACRS's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as PDSB (100) in the Pharmaceuticals Major industry. This means that ACRS’s stock grew similarly to PDSB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACRSPDSB
RSI
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
83%
Bullish Trend 4 days ago
84%
Momentum
ODDS (%)
Bullish Trend 4 days ago
86%
Bearish Trend 4 days ago
88%
MACD
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
82%
Bearish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
89%
Advances
ODDS (%)
Bullish Trend 11 days ago
80%
Bullish Trend 19 days ago
86%
Declines
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
79%
N/A
Aroon
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 4 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
ACRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MRSKF21.43N/A
N/A
DMG Mori Co Ltd
AUSTF0.25N/A
N/A
Austin Engineering Ltd.
FFMH41.79N/A
N/A
First Farmers & Merchants Corp.
ASRE0.04N/A
N/A
ASTRA ENERGY INC.
NWOEF4.64N/A
N/A
New Oriental Education & Technology Group, Inc.

ACRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACRS has been loosely correlated with MYNZ. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ACRS jumps, then MYNZ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACRS
1D Price
Change %
ACRS100%
N/A
MYNZ - ACRS
40%
Loosely correlated
-1.43%
IBRX - ACRS
34%
Loosely correlated
-3.23%
PDSB - ACRS
33%
Poorly correlated
-2.76%
ARCT - ACRS
33%
Poorly correlated
-7.49%
RXRX - ACRS
32%
Poorly correlated
-6.85%
More

PDSB and

Correlation & Price change

A.I.dvisor indicates that over the last year, PDSB has been loosely correlated with RXRX. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if PDSB jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PDSB
1D Price
Change %
PDSB100%
-2.76%
RXRX - PDSB
48%
Loosely correlated
-6.85%
ARCT - PDSB
47%
Loosely correlated
-7.49%
NRIX - PDSB
43%
Loosely correlated
+0.17%
DYN - PDSB
43%
Loosely correlated
-4.78%
DNLI - PDSB
43%
Loosely correlated
-2.69%
More